Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for...
BridgeBio Pharma
EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment
Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt
China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...